Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Placebo Placebo plus lifestyle therapy	lifestyle therapy after meal replacement induction; lifestyle: not reported	33	33
A2	Exenatide extended release 2 mg subcutaneous once weekly Exenatide extended release 2 mg weekly plus lifestyle therapy	lifestyle therapy after meal replacement induction; lifestyle: not reported	33	33

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Placebo A1	Exenatide extended release 2 mg subcutaneous once weekly A2	Whole trial ALL
age	mean (years)			16
age	sd (years)			1.5
bmi	mean (kg/m2)			36.9
bmi	sd (kg/m2)			4.4
female	n	13	18
hispanic	n	2	5

Analyses this trial contributes to

Percent BMI change
Children and adolescents with obesity; weeks 40 to 104 (target week 68); network meta-analysis
Percent BMI change
Children and adolescents with obesity; weeks 40 to 104 (target week 68); network meta-analysis
Serious adverse events
Children and adolescents with obesity; longest follow-up; network meta-analysis
Serious adverse events
Children and adolescents with obesity; longest follow-up; network meta-analysis
Nausea
Children and adolescents with obesity; longest follow-up; network meta-analysis
Nausea
Children and adolescents with obesity; longest follow-up; network meta-analysis
Vomiting
Children and adolescents with obesity; longest follow-up; network meta-analysis
Vomiting
Children and adolescents with obesity; longest follow-up; network meta-analysis
Diarrhea
Children and adolescents with obesity; longest follow-up; network meta-analysis
Diarrhea
Children and adolescents with obesity; longest follow-up; network meta-analysis
Constipation
Children and adolescents with obesity; longest follow-up; network meta-analysis
Constipation
Children and adolescents with obesity; longest follow-up; network meta-analysis

Results

16 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

Percent BMI change (4 lines; O13B)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
52	A1	percent change	10.1 percent	9.0		33	not stated; randomized; registry:outcomes
52	A2	percent change	4.6 percent	10.5		33	not stated; randomized; registry:outcomes
52	A2 vs A1	md	-4.1 percent		-8.6 to 0.5		not stated; randomized; R0009976:Abstract
52	A2 vs A1	md	-5.7 percent		-10.9 to -0.6		not stated; per protocol; R0009976:Abstract

All cause mortality (2 lines; O20)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				0 / 33	not stated; randomized; registry:adverse_events
	A2	events				0 / 33	not stated; randomized; registry:adverse_events

Serious adverse events (2 lines; O25)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				0 / 33	not stated; randomized; registry:adverse_events
	A2	events				1 / 33	not stated; randomized; registry:adverse_events

Nausea (2 lines; O27A)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				7 / 33	not stated; randomized; registry:adverse_events
	A2	events				13 / 33	not stated; randomized; registry:adverse_events

Vomiting (2 lines; O27B)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				2 / 33	not stated; randomized; registry:adverse_events
	A2	events				13 / 33	not stated; randomized; registry:adverse_events

Diarrhea (2 lines; O27C)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				6 / 33	not stated; randomized; registry:adverse_events
	A2	events				11 / 33	not stated; randomized; registry:adverse_events

Constipation (2 lines; O27D)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				6 / 33	not stated; randomized; registry:adverse_events
	A2	events				6 / 33	not stated; randomized; registry:adverse_events

NCT02496611

Design

Conduct and analysis

Arms

Baseline characteristics

Analyses this trial contributes to

Results